Cantor Fitzgerald made no change to the firm’s Overweight rating or $100 price target on BioMarin, but tells investors in a research note that BioMarin may be the firm’s favorite Biotech name for the year. The firm thinks BioMarin could bring in strategic interest, possibly sooner rather than later, but even without interest, the stock can work as a research pipeline and earnings growth story for 2024/2025, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BMRN Earnings this Week: How Will it Perform?
- Elliott Management bought BioMarin and Etsy during Q4, exited Arm
- BioMarin to present positive data on Roctavian durability at EAHAD Congress
- BioMarin reports Jeffrey Ajer to step down as Chief Commercial Officer
- William Blair biotech analysts to hold an analyst/industry conference call
